Dapirolizumab pegol not checked
UCB Biopharma SRL · CDP7657
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.”In the company’s words, NCT06617325 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erythematosus (3 trials)
- Main trialPhase 3
- “The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.”In the company’s words, NCT06617325 on ClinicalTrials.gov
- Other names
- DZP · CDP7657
Other drugs for Systemic Lupus Erythematosus
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis Pharmaceuticals · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
Coming up3
- 31 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- 7 Aug 2030Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07934472
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 May 2028 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | |
| Phase 3Enrolling by invitation | 7 Aug 2030 | A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus | |
| Phase 1Not yet recruiting | 31 Dec 2028 | A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol | |
| Phase 3Completed | 22 May 2024 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | |
| Phase 2Completed | 31 May 2018 | A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026